UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
GlaxoSmithKline plc
 
Results of Annual General Meeting
 
GlaxoSmithKline plc ('GSK') held its Annual General Meeting ('AGM') at 2.30pm on Wednesday 6 May 2020.
 
As a result of the COVID-19 pandemic and the prohibition on public gatherings of more than two people, the AGM was held as a closed meeting attended by the minimum necessary quorum of two shareholders. All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
 
All resolutions were passed at the AGM and the results of the poll are set out below. The full text of the resolutions considered at the AGM are contained in the Notice of AGM published on 23 March 2020 which is available on GSK's website at www.gsk.com.
 
Commenting after the shareholder webcast, which was held after the AGM, Sir Jonathan Symonds, Chairman, said "Despite the current crisis which unfortunately meant that we could not hold our AGM in the usual way, I was pleased that we could engage with our shareholders via the webcast and that we were able to answer a number of questions. I would like to thank shareholders for their participation and for their continued support and understanding in these exceptional times".
 
Resolution
Total votes for(1)(2)
%
Total votes against(2)
%
Total votes cast
Votes withheld(3)
1
Receive and adopt the 2019 Annual Report
3,600,444,466
99.14
31,207,913
0.86
3,631,652,379
10,956,841
2
Approve the Annual report on remuneration  
3,420,333,315
94.53
197,813,171
5.47
3,618,146,486
24,463,063
3
To approve the Remuneration policy
2,665,161,732
88.18
357,360,021
11.82
3,022,521,753
620,087,463
4
Election of Sir Jonathan Symonds
3,608,718,661
99.35
23,502,289
0.65
3,632,220,950
10,386,063
5
Election of Charles Bancroft
3,627,334,204
99.87
4,856,095
0.13
3,632,190,299
10,417,951
6
Re-election of Emma Walmsley
3,627,591,812
99.84
5,958,848
0.16
3,633,550,660
9,058,990
7
Re-election of Vindi Banga
3,610,251,798
99.39
22,061,718
0.61
3,632,313,516
10,290,761
8
Re-election of Dr Hal Barron
3,626,272,920
99.83
6,065,354
0.17
3,632,338,274
10,268,248
9
Re-election of Dr Vivienne Cox
3,610,563,927
99.39
21,999,262
0.61
3,632,563,189
10,044,077
10
Re-election of Lynn Elsenhans
3,625,704,253
99.82
6,692,345
0.18
3,632,396,598
10,211,321
11
Re-election of Dr Laurie Glimcher
3,627,888,440
99.87
4,570,015
0.13
3,632,458,455
10,149,465
12
Re-election of Dr Jesse Goodman
3,627,512,409
99.87
4,791,872
0.13
3,632,304,281
10,303,639
13
Re-election of Judy Lewent
3,555,987,248
97.90
76,330,162
2.10
3,632,317,410
10,290,509
14
Re-election of Iain Mackay
3,589,348,335
98.83
42,624,938
1.17
3,631,973,273
10,634,976
15
Re-election of Urs Rohner
3,566,736,006
98.27
62,967,560
1.73
3,629,703,566
10,694,898
16
Re-appointment of the auditor
3,629,594,188
99.89
4,085,942
0.11
3,633,680,130
8,926,613
17
Remuneration of auditor
3,628,076,303
99.86
4,927,253
0.14
3,633,003,556
9,605,108
18
Authority for the company to make donations to political organisations and incur political expenditure
3,535,034,521
97.51
90,339,692
2.49
3,625,374,213
17,230,899
19
Authority to allot shares
3,486,912,340
96.08
142,428,115
3.92
3,629,340,455
13,259,348
20
Disapplication of pre-emption rights - general power(4)
3,551,097,589
97.88
76,802,232
2.12
3,627,899,821
14,698,767
21
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4)
3,547,842,037
97.88
76,869,347
2.12
3,624,711,384
17,887,616
22
Authority for the company to purchase its own shares(4)
3,564,497,165
98.16
66,913,063
1.84
3,631,410,228
11,196,094
23
Exemption from statement of senior statutory auditor's name
3,584,838,016
98.78
44,131,049
1.22
3,628,969,065
13,635,791
24
Authority for reduced notice of a general meeting other than an AGM(4)
3,354,669,411
92.41
275,453,838
7.59
3,630,123,249
12,478,713
 
Notes:
 
(1)
The "for" votes include those giving the Chairman discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.

(2)
 
Votes "for" and "against" are expressed as a percentage of the total votes cast.
 
(3)
 
A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
 
(4)
 
Indicates Special Resolutions requiring a 75% majority.
 
 
 
The following table provides further relevant information:
 
 
 
 
GSK's
Twentieth
AGM
(2020)
 
GSK's
Nineteenth
AGM
(2019)
Issued share capital (excluding Treasury Shares)
5,017,091,542
4,987,806,108
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
72.60%
71.49%
Total shareholder population
105,353
108,698
Total number of proxies lodged
6,268
6,635
% of shareholders who lodged proxies
5.95%
6.10%
 
The above poll results will shortly be available on the Company's website at www.gsk.com. In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism 
 
 
 
 
V A Whyte
Company Secretary
 
6 May 2020
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: May 06, 2020
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc